References
- Donohue JF, Ohar JA. Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 3: 152–160
- Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126: 213–219
- Ellepola ANB, Samaranayake LP. Inhalational and topical steroids and oral candidiasis: a mini review. Oral Dis 2001; 7: 211–216
- Jackson LD, Polygenis D, Mcivor RA. Comparative efficacy and safety of inhaled corticosteroids in asthma. Can J Clin Pharmacol 1999; 6: 26–37
- Kuna P. Long-term effects of steroid therapy. Wiad Lek 1998; 51: 12–18
- Lipworth BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther 1993; 58: 173–209
- Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989; 18: 554–564
- Spector SL, Wangaard C, Bardana EJ, Jr. The use of cultures and immunologic procedures to predict oropharyngeal candidiasis in patients on steroid aerosols. Clin Allergy 1982; 12: 269–278
- Willey RF, Milne LJ, Crompton GK, Grant IW. Beclomethasone dipropionate aerosol and oropharyngeal candidiasis. Br J Dis Chest 1976; 70: 32–38
- Milne LJ, Crompton GK. Beclomethasone dipropionate and oropharyngeal candidiasis. Br Med J 1974; 3: 797–798
- Vogt FC. The incidence of oral candidiasis with the use of inhaled corticosteroids. Ann Allergy 1979; 43: 205–210
- Salzman GA, Pyszczynski DR. Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered dose inhaler alone and with Aerochamber. J Allergy Clin Immunol 1988; 81: 424–428
- Toogood JH. Complications of topical steroid therapy for asthma. Am Rev Respir Dis 1990; 141: S89–S96
- Klein RS, Carol AH, Small CB, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Eng J Med 1984; 311: 354–358
- Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339–346
- Chakir J, Cote L, Coulombe C, Deslauriers N. Differential pattern of infection and immune response during experimental oral candidiasis in BALB/c and DBA/2 (H-2d) mice. Oral Microbiol Immunol 1994; 9: 88–94
- Elahi S, Pang G., Clancy R, Ashman RB. Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis. Infect Immun 2000; 68: 5771–5777
- Samaranayake YH, Samaranayake LP. Experimental oral candidiasis in animal models. Clin Microbiol Rev 2001; 14: 398–429
- Walsh TJ, Gonzalez CE, Piscitelli S, et al. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol 2000; 38: 2369–2373
- Takakura N, Sato Y, Ishibashi H, et al. A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiol Immunol 2003; 47: 321–326
- Maebashi K, Itoyama T, Uchida K, Suegara N, Yamaguchi H. A novel model of cutaneous candidiasis produced in prednisolone-treated guinea-pigs. J Med Vet Mycol 1994; 32: 349–359